Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly D-cycloserine for Cognition in Schizophrenia
NCT00964041Phase 4Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- Jul 2009
- Primary completion
- Jun 2011
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in schizophrenia and schizoaffective disorder comparing D-cycloserine with Placebo (2 arms). Primary endpoint: Effect of repeated weekly dosing of D-cycloserine on performance on a standard cognitive battery at 8 weeks. Planned start Jul 2009; status: withdrawn.
02
Drugs
d-cycloserine
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT00964041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00964041.